TNDM NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Tandem Diabetes Care Inc · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 17.12 USD
0.2% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -10.0% below the Trend Line and sits at 36.3% of its 52-week range. The latest completed week returned 0.2%, after a 5.4% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. Options positioning is bullish with 39/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 29 out of 100
Latest Close 17.12 USD 24 Jul 2026
1W Return 0.2% latest completed week
4W Return 5.4% short-term follow-through
12W Return -11.8% quarterly tape
Trend Breadth 36.5% 19 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.2% Latest completed week; four-week move 5.4%. Indicator stack 20/38 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 39/100 conviction; expected move 27.7%. News sentiment 55/100 58 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -10.0% below the Trend Line and sits at 36.3% of its 52-week range. The latest completed week returned 0.2%, after a 5.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0612-week average 0.16

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.06Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 5.4% over four weeks, -11.8% over 12 weeks, and 7.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W0.2%
4W5.4%
12W-11.8%
26W-14.0%
52W7.7%
Active trend streak0 weeks
Active weeks in one year19
Trend breadth36.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.67Latest activity-pressure read.
Pressure change6.7%Four-week change in activity pressure.
Leadership-11.42Latest relative-leadership reading.
RS change42.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 85% Model confidence 81%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength6/100Blend of value, momentum, and quality. Underlying universe rank 95; rank 1 is best.
Value19/100Relative valuation strength. Underlying universe rank 82; rank 1 is best.
Quality9/100Profitability and accounting quality. Underlying universe rank 92; rank 1 is best.
Momentum31/100Medium-term price momentum. Underlying universe rank 70; rank 1 is best.
Growth19/100Revenue and earnings growth. Underlying universe rank 82; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
1.1x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
2.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
54.9%
Gross profit retained from each unit of revenue.
Operating margin
-8.7%
Operating profit retained from revenue.
Free-cash-flow margin
4.2%
Free cash flow generated from revenue.
Return on invested capital
-9.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-6.8%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
35.3%
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.2%
Net share repurchases relative to market value.
Shareholder yield
0.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-7.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

TNDM shows bullish options pressure with a 39/100 conviction score, put-call volume ratio of 0.31, expected move of 27.7%, and Sharemaestro trend signal inactive.

Conviction39/100
Expected move27.7%
Put/call volume0.31
Pressure60
Speculation5
Volatility96
Trend agreement13
Open options detail
Insider activity12 / 8

12 acquisitions and 8 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment55/100

Weighted news tone is neutral across 58 relevant articles.

13 positive · 42 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move27.7%Nearest-chain priced movement where available.
52-week drawdown-42.3%Distance below the 52-week high.
13-week volatility11.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+29.7%Week of 20 Feb.
Worst week-20.3%Week of 8 May.
Latest week+0.2%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains5
Flat weeks0
Modest losses4
Sharp losses9
Recent vol11.9%13-week weekly-return volatility.
Base vol10.7%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew8.2% / -7.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape27/100

Trend, activity pressure, participation, and risk combine to a 27/100 tape read.

 Indicator analysis9/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.06; No reversal markers Factors14/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 39; Small Cap Core rank 82 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options44/100

TNDM shows bullish options pressure with a 39/100 conviction score, put-call volume ratio of 0.31, expected move of 27.7%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 27.7% Sentiment55/100

Weighted news tone is neutral across 58 relevant articles.

UBS Adjusts Price Target on Tandem Diabetes Care to $18 From $22, Maintains Neutral Rating Insiders12 / 8

12 acquisitions and 8 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202617.12 USD0.2%19.03 USD25.75 USD-0.67-11.427.5MOff
17 Jul 202617.08 USD10.8%19.20 USD25.87 USD-0.78-13.239.2MOff
10 Jul 202615.41 USD0.6%19.37 USD25.98 USD-1.02-25.067.1MOff
3 Jul 202615.32 USD-5.7%19.57 USD26.07 USD-0.92-24.515.6MOff
26 Jun 202616.24 USD6.1%19.75 USD26.13 USD-0.72-19.7613.8MOff
19 Jun 202615.30 USD-7.8%19.91 USD26.18 USD-0.80-28.378.2MOff
12 Jun 202616.60 USD-14.2%20.11 USD26.24 USD-0.78-21.1514.1MOff
5 Jun 202619.34 USD12.4%20.18 USD26.31 USD-0.96-7.0214.1MOff
29 May 202617.20 USD14.9%20.08 USD26.35 USD-1.17-21.6412.6MOff
22 May 202614.96 USD16.7%19.97 USD26.39 USD-1.09-30.5313.2MOff
15 May 202612.82 USD-17.2%19.97 USD26.47 USD-0.98-40.5217.5MOff
8 May 202615.48 USD-20.3%20.03 USD26.57 USD-0.84-29.5917.0MOff
1 May 202619.42 USD-4.6%19.98 USD26.68 USD-0.78-8.268.7MOff
24 Apr 202620.36 USD-1.2%19.83 USD26.78 USD-0.81-3.247.5MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.